ReNeuron touts promising results from stem cell trial

05/17/2013 | Bloomberg

Researchers are set to announce positive results from a trial of ReNeuron Group's stem cell treatment for the damage caused by stroke, CEO Michael Hunt said. The findings are expected to be presented this month at a conference in London. "It sets us up nicely for a Phase II efficacy trial," said Hunt.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC